Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;17(1):28-41.
doi: 10.1111/ajt.14107.

The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology

Free PMC article

The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology

A Loupy et al. Am J Transplant. .
Free PMC article


The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i-IFTA score, comprising inflammation within areas of fibrosis and atrophy and acceptance of transplant arteriolopathy within the descriptions of chronic active T cell-mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histologic, serologic, and molecular diagnostic techniques to produce a consensus-based reporting system that offers precise composite scores, accurate routine diagnostics, and applicability to next-generation clinical trials.

Keywords: clinical research/practice; kidney transplantation/nephrology; organ transplantation in general; pathology/histopathology; rejection; rejection: T cell mediated (TCMR); rejection: antibody-mediated (ABMR); rejection: subclinical; translational research/science.


Figure 1
Figure 1
Molecular lesions and their corresponding histologic lesions in T cell–mediated rejection and antibody‐mediated rejection in kidney allografts. cg, glomerular double contours; cv, vascular fibrous intimal thickening; i, inflammation; ptc, peritubular capillaritis; ti, total inflammation; v, intimal arteritis.

Similar articles

See all similar articles

Cited by 97 articles

See all "Cited by" articles


    1. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d‐negative antibody‐mediated rejection and antibody‐associated arterial lesions. Am J Transplant 2014; 14: 272–283. - PubMed
    1. Sis B, Mengel M, Haas M, et al. Banff ‘09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464–471. - PubMed
    1. Sis B, Bagnasco SM, Cornell LD, et al. Isolated endarteritis and kidney transplant survival: A multicenter collaborative study. J Am Soc Nephrol 2015; 26: 1216–1227. - PMC - PubMed
    1. Mengel M, Chan S, Climenhaga J, et al. Banff initiative for quality assurance in transplantation (BIFQUIT): Reproducibility of C4d immunohistochemistry in kidney allografts. Am J Transplant 2013; 13: 1235–1245. - PubMed
    1. Farris AB, Chan S, Climenhaga J, et al. Banff fibrosis study: Multicenter visual assessment and computerized analysis of interstitial fibrosis in kidney biopsies. Am J Transplant 2014; 14: 897–907. - PubMed

Publication types

MeSH terms

Grant support